FDA & Compounded GLP-1 in 2026: What the Enforcement Actions Actually Mean for Patients
By Chad Simpson · Updated May 6, 2026
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
What this page covers
The FDA’s 2025 enforcement actions against compounded GLP-1s targeted bulk 503B manufacturing — not patient-specific 503A compounding. This page explains what FDA authority actually covers, what the enforcement actions were about, and what patients should verify when using a telehealth provider for compounded GLP-1.
What the FDA Says About Compounded GLP-1s
The FDA has authority over drug compounding under the Federal Food, Drug, and Cosmetic Act (FDCA). Within that authority, there are two distinct legal frameworks for compounding — and FDA treats them differently.
For 503A pharmacies (patient-specific compounding): FDA has regulatory authority as a backstop, but primary oversight is at the state level through state boards of pharmacy. Patient-specific compounding under a physician’s prescription is protected under FDCA Section 503A and has not been the target of FDA’s 2025 enforcement actions against GLP-1 manufacturers.
For 503B outsourcing facilities (bulk manufacturing): FDA has direct oversight authority and requires compliance with current Good Manufacturing Practice (cGMP) standards. During the GLP-1 drug shortage, 503B facilities had broader authority to produce compounded GLP-1s. After the shortage was resolved, FDA moved to enforce against 503B bulk manufacturing of GLP-1s that lacked valid shortage justification.
Key takeaway: FDA’s position is not a blanket prohibition on compounded GLP-1s. It is a targeted enforcement position against a specific category of large-scale bulk manufacturing. Patient-specific 503A compounding under a physician’s prescription continues within the legal framework.
The Shortage-to-Enforcement Timeline: 4 Key Dates
2021–2023
GLP-1 shortage declared; compounding authority expands
FDA places semaglutide (and later tirzepatide) on its drug shortage list. Under FDCA, the shortage designation gives both 503A pharmacies and 503B outsourcing facilities expanded authority to compound these medications. Demand for GLP-1 medications was dramatically outpacing commercial supply.
Late 2024
FDA resolves semaglutide shortage; warning letters begin
FDA officially declares the semaglutide shortage resolved. The legal basis for 503B bulk compounding of semaglutide narrows. FDA begins sending warning letters to some 503B outsourcing facilities that continued large-scale production without valid shortage justification. 503A patient-specific compounding under physician prescriptions is unaffected.
March–May 2025
Tirzepatide shortage resolved; 503B enforcement actions
FDA resolves the tirzepatide shortage. FDA issues enforcement actions — including warning letters and import alerts — targeting 503B outsourcing facilities that were bulk-manufacturing compounded tirzepatide at industrial scale without valid shortage justification. Headlines read as a broad GLP-1 ban, but the actual target was bulk 503B manufacturing specifically.
2026 (current status)
503A patient-specific compounding continues legally
Patient-specific 503A compounded semaglutide and tirzepatide, prepared under valid physician prescriptions, continues to operate within the legal framework. Legitimate telehealth platforms using licensed 503A pharmacies and requiring physician prescriptions remain within FDA's stated tolerance for patient-specific compounding.
What FDA’s Enforcement Actions Were Actually About
The 2025 enforcement actions were specifically about bulk 503B manufacturing at scale — a category that is fundamentally different from patient-specific 503A compounding. Understanding this distinction is the key to reading the enforcement actions accurately.
What enforcement DID target (503B)
- Large-scale outsourcing facilities producing millions of doses
- Bulk manufacturing without patient-specific prescriptions
- Production at commercial pharmaceutical scale
- Facilities operating without valid shortage justification after shortage ended
- Some facilities with cGMP compliance failures
What enforcement did NOT target (503A)
- Patient-specific compounding for individual patients
- Licensed state pharmacies with valid physician prescriptions
- Small-batch compounding with patient-specific formulations
- Telehealth platforms using 503A pharmacy partners
- 503A pharmacies meeting USP 795/797 standards
Why the headlines were misleading: News coverage of the 2025 enforcement actions often framed it as “FDA cracks down on compounded GLP-1s” — which is technically accurate but omits the critical distinction between 503A patient-specific compounding and 503B bulk manufacturing. Most patients seeking compounded GLP-1 through telehealth are in the 503A framework, not the 503B framework that was targeted.
FDA’s Practical Guidance for Patients
FDA has been consistent in its practical guidance for patients seeking compounded GLP-1 medications:
Work with a licensed physician
A valid prescription from a licensed physician, NP, or PA is the legal foundation of the 503A framework. No medication should be dispensed without a prescription from a licensed prescriber who has reviewed your health information.
Use a licensed 503A compounding pharmacy
The compounding pharmacy should be licensed by the relevant state board of pharmacy. Patients can verify pharmacy licenses through their state board of pharmacy website.
Avoid gray-market or prescription-free sources
FDA has specifically flagged gray-market GLP-1 sources — platforms that allow purchase without a physician consultation or prescription. These sources operate outside the legal framework and carry compounding quality risks.
Avoid unusually low-priced sources with no medical infrastructure
GLP-1 compounding involves licensed pharmacists, physician oversight, regulated active pharmaceutical ingredients, and ongoing quality control. Sources offering compounded tirzepatide or semaglutide at very low prices with no verifiable medical team should raise safety and legality questions.
Providers Operating Within FDA’s Framework
These telehealth providers use licensed 503A pharmacies, require physician prescriptions, and operate within the legal framework that FDA has consistently recognized for patient-specific compounding:
Eden Health
Requires bloodwork at intake. Strong regulatory transparency. Physician-supervised prescribing with licensed 503A pharmacy.
TMates
Physician-supervised; competitive pricing; licensed 503A compounding pharmacy partners.
MEDVi
Explicit 503A pharmacy partnerships. Physician-led with transparent supply chain.
Frequently Asked Questions
What is FDA's position on compounded semaglutide and tirzepatide?
FDA's position is nuanced by pharmacy type. For 503B outsourcing facilities: after the drug shortages were resolved in 2024–2025, FDA moved to restrict bulk compounding without valid shortage justification, resulting in enforcement actions against some 503B manufacturers. For 503A pharmacies: patient-specific compounding with a valid physician prescription continues to operate within the legal framework under FDCA Section 503A.
Did the FDA ban compounded GLP-1 medications?
No. FDA did not ban compounded GLP-1 medications broadly. The 2025 enforcement actions targeted specific 503B outsourcing facilities engaged in bulk manufacturing after the shortage designation ended. Patient-specific 503A compounding under a physician's prescription was not the target of those actions and continues to operate legally.
What happened with the GLP-1 drug shortage?
FDA placed semaglutide on the drug shortage list around 2021 and tirzepatide later. The shortage designation gave pharmacies broader authority to compound these medications. FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025. After shortage resolution, the legal basis for large-scale 503B bulk compounding narrowed, triggering enforcement actions.
What is the difference between 503A and 503B for FDA regulation?
503A pharmacies compound patient-specific medications under valid physician prescriptions and are regulated primarily by state boards of pharmacy with FDA as a backstop. 503B outsourcing facilities are large-scale manufacturers subject to FDA cGMP standards and direct federal oversight. FDA's 2025 enforcement actions targeted 503B facilities, not 503A pharmacies.
Is it safe to use compounded GLP-1 from a telehealth provider?
Safety depends on the source. Compounded GLP-1 from a licensed 503A pharmacy operating under a physician's prescription uses a regulated, state-licensed compounding facility subject to USP standards. Key safety factors: use a reputable telehealth provider with physician oversight, confirm the 503A pharmacy license, ensure ongoing medical monitoring. Avoid gray-market sources that require no prescription.
What should patients verify when choosing a compounded GLP-1 provider?
Verify four things: (1) A licensed physician issues a prescription before any medication is dispensed. (2) The platform uses a 503A licensed compounding pharmacy — not 503B. (3) The pharmacy is licensed in your state. (4) The platform has a verifiable licensed medical team and transparent pharmacy partnerships.
Related Articles
Related Guides
Continue your research with these related independent reviews.